References
- FerlayJShinHRBrayFFormanDMathersCParkinDMEstimates of worldwide burden of cancer in 2008: GLOBOCAN 2008Int J Cancer2010127122893291721351269
- HowladerNNooneAMKrapchoMSEER Cancer Statistics Review 1975–2008National Cancer InstituteBethesda, MD2011 [updated 2010 November, posted 2011]. Available from: http://seer.cancer.gov/csr/1975_2008/Accessed August 8, 2011
- PontesLSilvaMAMatosoFRegisto Oncológico Nacional 2005 [National Cancer Registry 2005]PortugalRegisto Oncológico Regional Centro2009
- ParenteBQueirogaHTeixeiraEEstudo epidemiológico do cancro do pulmão em Portugal nos anos de 2000/2002 [Epidemiologic study of lung cancer in Portugal from 2000 to 2002]Rev Port Pneumol200713225526517571453
- Sotto-MayorRMarcos históricos no estudo do cancro do pulmãoRev Port Pneumol200612440144616969572
- SandlerAGrayRPerryMPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
- SandlerABevacizumab in non-small cell lung cancerClin Cancer Res200713154613s4616s
- ReckMvon PawelJZatloukalPPhase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiLJ Clin Oncol20092781227123419188680
- ReckMvon PawelJZatloukalPOverall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)Ann Oncol20102191804180920150572
- FolkmanJMerlerEAbernathyCGretchenWIsolation of a tumor factor responsible for angiogenesisJ Exp Med197113322752884332371
- FerraraNHillanKGerberHNovotnyWDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNat Rev Drug Discov20043539140015136787
- BarlesiFde CastroJDvornichenkoVAVAPERL (MO22089): final efficacy outcomes for patients (pts) with advanced non-squamous non-small cell lung cancer (nsNSCLC) randomised to continuation maintenance (mtc) with bevacizumab (bev) or bev+pemetrexed (pem) after first-line (1L) bev-cisplatin (cis)-pem treatment (Tx)Paper presented at: 2011 European Multidisciplinary Cancer CongressSeptember 23–27, 2011Stockholm, Sweden.
- CohenMGootenbergJKeeganPPazdurRFDA Drug approval summary: bevacizumab (avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancerOncologist200712671371817602060
- InfarmedRelatório de avaliação prévia de medicamento para uso em meio hospitalar [Preliminary report on drug use in hospital environment]Lisbon, PortugalAutoridade Nacional do Medicamento e Produtos de Saúde I.P2010
- PhillipsBSackettDBadenochDOxford Centre for Evidence-based Medicine – Levels of Evidence (March 2009) Available from: http://www.cebm.net/index.aspx?o=1025Acessed August 30, 2011
- CrinòLDansinEGarridoPSafety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 studyLancet Oncol201011873374020650686